Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
Date:12/1/2008

MORRISTOWN, N.J., Dec. 1 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 150mg. Distribution of the product has commenced.

Bupropion Hydrochloride extended-release tablets (XL), available in 150 & 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual U.S. sales of brand and generic Wellbutrin XL(R) were US$1,481 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"Bupropion XL 150mg, together with 300mg which was launched in August this year, offers significant value to our customers and patients. This approval also underscores Actavis' emphasis and capability in bringing complex controlled-release products to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
2. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
3. Actavis Extends Portfolio With Four New Products in the U.S.
4. Actavis Confirms its Patent Challenge of Kings Avinza(R)
5. Actavis Launches Amlodipine Tablets in the U.S.
6. Actavis Launches Carvedilol Tablets in the U.S.
7. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
8. EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
9. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
10. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
11. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... chains are often blamed for the increasing rates ....au however finds that 80% of people think that pa... (PRWEB) November 9, 2009 -- If ... behind Australia’s obesity epidemic, think ...standers. A recent survey commissioned for Fitnes...
(Date:11/9/2009)...o be Offered in April 2010, Provides First Respond... Cambridge, MA (Vocus) November 9, 2009 -- Whe...HR) first inspected a suspected mass grave at Das...eed a team of experts to help interpret the scene....key first step in securing evidence of a human rig...
(Date:11/9/2009)...ncer Network (NCCN) has posted a draft white paper...for near-term comparative effectiveness clinical e...introduces the NCCN Comparative Therapeutic Index(... the risk-versus-benefit of different treatment op...idelines in Oncology(TM). The paper will be posted...
(Date:11/9/2009)...swire/ -- Health Connect Partners, Inc., ( www.hl...ugural Hospital O.R. and Surgery Center Conference...e Hotel in Nashville, Tenn. ,, Health Connect P...ing room directors and managers from some of the l.... Some of the confirmed providers include HCA, Bon...
(Date:11/9/2009)...-- Highlighting a commitment to providing long-ter...ent and digital display technology options, LG Ele...nd Hospital Grade LCD HDTVs this week at the Assoc...nual meeting and exposition (booth #1760). ,, O...ew(TM)" Long-Term Care LCD HDTVs bring a sense of ...
Breaking Medicine News(10 mins):Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4Health News:Health Connect Partners Hosts Hospital O.R. & Surgery Center Conference 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5
...ransmitter dopamine has long been known to play a ... mutations in a protein called parkin// cause a fo... scientists, reporting in the Jan. 31 issue of The... researchers show for the first time that a mutate...
...ly aggressive treatment with disease-modifying ant...reventing joint damage and avoiding the// fate of ...idely prescribed and generally safe methotrexate, ...sease, which is marked by chronic inflammation of ...
...ium picolinate published in the current edition of...t chromium picolinate is //effective in improving ...eople with type 2 diabetes. The review, whic...zed efficacy after combining results from all type...
...gainst exposing their unborn baby to a 3D ultrasou...such a move is fraught with risks. This// advice h... growing popularity of three dimensional ultrasoun... in 2005, so that they could monitor their baby’s ...
... simple, safe and cost-effective dipstick for the ...ay its low cost, sensitivity and ease of// use mak...gesh Tripathi and colleagues at the India-based De...rated into a dipstick that shows a brown dot if a ...
...ff for a week of sun, snow, and après-ski. And whi...onsider the dangers of skin// cancer? It is ...e than 69,000 new cases reported every year. The i...ferent nationalities behave while having fun in th...
Other Medicine News:Health News:UCLA Find Yields Further Insight into Causes of Parkinson’s Diseas 2Health News:Rheumatoid Arthritis: Early Aggressive Treatment Needed 2Health News:Chromium Picolinate Effective for Diabetes Care 2Health News:Chromium Picolinate Effective for Diabetes Care 3Health News:The Psychology of Skin Cancer 2
(Date:11/9/2009)... Facet Solutions, Inc. today announced that it has...trolled ACADIA(TM) IDE study for lumbar spinal ste...009," stated President and CEO, Geoff Pardo. "It i...omes that surgeons are seeing, and the ease with w...on people are diagnosed with lumbar spinal stenosi...
(Date:11/9/2009).... 9 Hill-Rom (NYSE: H...tion of a joint venture that will focus on the sal...face replacement systems that are intended to be s...for surfaces that are technologically obsolete or ...al leader in patient support systems and related t...
(Date:11/9/2009)...e/ -- Momentum is building for the early December...ond P-MEC India pharma ingredients, services and t...exhibitors from over 80 countries are expected...ts, being held on 1 - 3 December. ,, In additi...lude two new launches. BioPh India will focus on...
Breaking Medicine Technology:Facet Solutions Enrolls 100th Patient in US Pivotal IDE Study 2Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5Forecast Looks Good for India Pharma Shows 2Forecast Looks Good for India Pharma Shows 3While you were sleeping 47771 1While you were sleeping 47771 2Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers 47769 1Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers 47769 2ESC Congress 2009 3A Worlds biggest cardiology meeting to be held in Barcelona 47767 1ESC Congress 2009 3A Worlds biggest cardiology meeting to be held in Barcelona 47767 2
...led to Reach Statistical ...Y HILLS, Mass., Dec. 5 /PRNewswire-,FirstCall/ -- ...nd its,wholly- owned subsidiary, Unither Pharmaceu...eir two pivotal trials of OvaRex(R) MAb for the,tr...alysis demonstrates,that the studies failed to rea...
...r Patients, ROCKVILLE, Md., Dec. 4 EntreMed, Inc...l company developing,therapeutics for the treatmen...nced that it has commenced a multi-center Phase 2 ...d pancreatic cancer. The primary objectives,of thi...y of,orally-administered MKC-1 in unresectable or ...
Other Medicine Technology:Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 2Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 3Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint 4EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer 2EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer 3EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer 4
SYNCHRON LX®20 PRO
BN100
Bilitec 2000 Recorder
...y, pathology specimen imaging is now advancing tow...tion, analysis, interpretation and telepathology. ...gous to the change that occurred in radiology, and...departments and imaging clinics through the introd...
Medicine Products: